Functional Skills
Campaign Optimization
Commercial Strategy
Content Marketing
Customer Relationship Management
Market Access Strategy
Market Research
Market Penetration
Marketing Strategy
Product Launch
Strategic Planning
Brand Strategy
Competitive Landscaping
Digital Marketing / Advertising
Go-to-market Strategy
Product Marketing
Software Skills
Veeva Vault
Google Docs
Google Sheets
Microsoft Excel
Microsoft Office
Microsoft OneDrive
Microsoft PowerPoint
Microsoft Word
OpenAI
Outlook
Salesforce
Sector Experience
Healthcare
Life Sciences & Pharma
Technology
Fortune 500
Experience
Omeros Corporation
Product Management / Strategy
Associate Director, Brand Lead – Hematology/Oncology
3/2022 - 7/2025
(Narsoplimab): Seattle, WA / Whitefish, MT March 2022 – July 2025
● Served as the commercial lead for pre-launch strategy of narsoplimab, translating clinical development milestones into early commercial strategies including digital disease education campaigns, HCP marketing tools, and stakeholder mapping to prepare the market in advance of regulatory submission.
• Built and executed a multi-channel disease awareness campaign that delivered 32,000+ HCP/patient website visits and 300+ HCP tool downloads. Campaign strategy contributed to 45% growth in unaided disease awareness among transplanters in pre-launch market research.
• Oversaw development of HCP promotional assets (Core Visual Aids, leave-behinds, digital content), ensuring PRC compliance via Veeva Vault.
• Conducted competitive landscape and messaging scans across complement inhibitors to support indication prioritization for the MASP-3 pipeline program, highlighting key unmet need points for future positioning.
• Provided commercial feedback into Target Product Profile (TPP) discussions for pipeline indications, benchmarking against competitor trial designs and value messaging to recommend differentiation strategies and strengthen alignment with market needs.
• Managed Veeva Vault content management and CRM integration for HCP and patient campaigns, incorporating AI-assisted core claims management to ensure materials were compliant, up-to-date, and easily accessible for field teams and automated email.
● Served as the commercial lead for pre-launch strategy of narsoplimab, translating clinical development milestones into early commercial strategies including digital disease education campaigns, HCP marketing tools, and stakeholder mapping to prepare the market in advance of regulatory submission.
• Built and executed a multi-channel disease awareness campaign that delivered 32,000+ HCP/patient website visits and 300+ HCP tool downloads. Campaign strategy contributed to 45% growth in unaided disease awareness among transplanters in pre-launch market research.
• Oversaw development of HCP promotional assets (Core Visual Aids, leave-behinds, digital content), ensuring PRC compliance via Veeva Vault.
• Conducted competitive landscape and messaging scans across complement inhibitors to support indication prioritization for the MASP-3 pipeline program, highlighting key unmet need points for future positioning.
• Provided commercial feedback into Target Product Profile (TPP) discussions for pipeline indications, benchmarking against competitor trial designs and value messaging to recommend differentiation strategies and strengthen alignment with market needs.
• Managed Veeva Vault content management and CRM integration for HCP and patient campaigns, incorporating AI-assisted core claims management to ensure materials were compliant, up-to-date, and easily accessible for field teams and automated email.
Omeros Corporation
Marketing
Senior Marketing Manager, Hematology/Oncology
9/2019 - 3/2022
• Developed and executed KOL peer-to-peer strategy to validate brand messaging and increase disease recognition, including advisory boards and speaker bureau programming across high priority transplant centers. The bureau reached ~80% of target business pre-launch.
• Led five global advisory boards with hematology/transplant thought leaders, capturing insights that shaped trial differentiation, disease positioning, and stakeholder segmentation strategies.
• Directed company presence at key hematology/transplant congresses (ASH, EHA EBMT, Tandem), increasing HCP booth traffic year-over-year and capturing 500+ qualified HCP leads for follow-up engagement.
• Supported brand market research, synthesizing input from 50+ HCP interviews and competitor intelligence reports into commercial recommendations for brand messaging.
• Owned annual pre-launch brand planning and promotional budget (~$3M), improving budget variance across functions and aligning spend with pipeline milestones.
• Led five global advisory boards with hematology/transplant thought leaders, capturing insights that shaped trial differentiation, disease positioning, and stakeholder segmentation strategies.
• Directed company presence at key hematology/transplant congresses (ASH, EHA EBMT, Tandem), increasing HCP booth traffic year-over-year and capturing 500+ qualified HCP leads for follow-up engagement.
• Supported brand market research, synthesizing input from 50+ HCP interviews and competitor intelligence reports into commercial recommendations for brand messaging.
• Owned annual pre-launch brand planning and promotional budget (~$3M), improving budget variance across functions and aligning spend with pipeline milestones.
Janssen Pharmaceuticals (Johnson & Johnson)
Product Management / Strategy
Global Market Access & Health Policy Manager – IMBRUVICA (Hematologic
4/2016 - 8/2019
• Supported global market access strategy for Imbruvica across multiple B-cell malignancies, including Waldenström's Macroglobulinemia (WM) and CLL, during a period of significant label expansions and reimbursement assessments across Europe.
• Developed payer evidence tools (global value dossiers, cost-effectiveness models, systematic reviews) that were used to support HTA submissions across EU5 and global markets, contributing to positive reimbursement outcomes in several major European countries.
• Partnered with regional affiliates to adapt evidence packages during critical HTA reviews, including Germany's G-BA process, France's HAS assessment, and NICE CDF entry in the UK, helping reduce time-to-reimbursement in key launch markets.
• Collaborated with HEOR and epidemiology teams on RWE strategy to demonstrate disease burden and unmet need, strengthening payer positioning and directly influencing 3 major HTA approvals.
• Developed payer evidence tools (global value dossiers, cost-effectiveness models, systematic reviews) that were used to support HTA submissions across EU5 and global markets, contributing to positive reimbursement outcomes in several major European countries.
• Partnered with regional affiliates to adapt evidence packages during critical HTA reviews, including Germany's G-BA process, France's HAS assessment, and NICE CDF entry in the UK, helping reduce time-to-reimbursement in key launch markets.
• Collaborated with HEOR and epidemiology teams on RWE strategy to demonstrate disease burden and unmet need, strengthening payer positioning and directly influencing 3 major HTA approvals.
Boston Scientific
Marketing
Health Economics & Government Affairs Manager
7/2015 - 12/2015
Placement – Cardiac Electrophysiology): Hemel Hempstead, UK July 2015 – Dec 2015
● Built cost-effectiveness models for atrial fibrillation procedures within NHS trusts, highlighting economic value drivers that informed hospital adoption and policy discussions.
• Collaborated with commercial and clinical teams to create payer-facing communication resources, and trained field staff on integrating health economic tools into HCP conversations.
• Delivered analyses that shaped early market development strategies for novel electrophysiology technologies.
● Built cost-effectiveness models for atrial fibrillation procedures within NHS trusts, highlighting economic value drivers that informed hospital adoption and policy discussions.
• Collaborated with commercial and clinical teams to create payer-facing communication resources, and trained field staff on integrating health economic tools into HCP conversations.
• Delivered analyses that shaped early market development strategies for novel electrophysiology technologies.
Cornerstone Research
Research
Research Associate – Health Economics & Outcomes
5/2013 - 8/2013
Research (Summer Internship - HEOR): Burlington, ON, Canada May 2013 – Aug 2013
● Conducted systematic literature reviews and cost analyses to support oncology and rare disease market access submissions in North America and Europe.
• Contributed to global value dossiers and epidemiology-driven demand forecasts that informed early product positioning and reimbursement strategies.
• Partnered with senior consultants on HEOR projects, providing data analysis that supported successful client submissions to payers and regulators.
● Conducted systematic literature reviews and cost analyses to support oncology and rare disease market access submissions in North America and Europe.
• Contributed to global value dossiers and epidemiology-driven demand forecasts that informed early product positioning and reimbursement strategies.
• Partnered with senior consultants on HEOR projects, providing data analysis that supported successful client submissions to payers and regulators.
Europe-Economics
Research
Research Assistant – Health Policy & Economics
9/2012 - 12/2012
Placement): London, UK Sept 2012 – Dec 2012
● Developed elements of a cost-benefit framework for Phase III oncology trial site selection, incorporating EU regulatory and payer considerations to guide global development planning.
• Supported economic modeling and policy analyses for healthcare and life sciences clients, sharpening insights into how market access environments shape R&D investment decisions.
● Developed elements of a cost-benefit framework for Phase III oncology trial site selection, incorporating EU regulatory and payer considerations to guide global development planning.
• Supported economic modeling and policy analyses for healthcare and life sciences clients, sharpening insights into how market access environments shape R&D investment decisions.